We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Growing European Demand for Mad Cow Test

By HospiMedica staff writers
Posted on 29 Jan 2001
U.S. company Bio-Rad Laboratories (Hercules, CA) has become a leading provider of tests for bovine spongiform encephalopathy (BSE) in Europe. The company reports it has received orders for more than one million enzyme-linked immunosorbent assays (ELISA) for BSE, known as mad cow disease.

Since October 2000, the fear of BSE has spread quickly throughout Europe, as more cattle were found with the disease. Cows with BSE have been discovered in France, Germany, Spain, Portugal, and Italy. On January 1, 2001, the countries of the European Union commenced mandatory testing of all beef livestock over the age of 30 months in order to insure the highest quality and safety of the European food chain. According to media reports, seven million cattle will have to be tested in Europe this year.

Called Platelia, Bio-Rad's test was selected by the European Commission (EC) as one of the three most sensitive BSE tests and is among the three approved in the most recent EC report. Two independent reports commissioned by a directorate of the EC further substantiated Bio-Rad's test as the preferred test for diagnosing BSE in European cattle. The test is in a screening format for use in high throughput environments, providing results in about four hours.

To meet the demand for tests, Bio-Rad has increased manufacturing capabilities at its French facilities and is mobilizing employees around the world to support the scaling up of production. "We have allocated substantial resources to ensure that we can rapidly meet the growing needs for a quick, clear, and accurate test,” said David Schwartz, president and CEO of Bio-Rad.



Related Links:
Bio-Rad

New
Gold Member
X-Ray QA Meter
T3 AD Pro
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Hospital Data Analytics Software
OR Companion
New
X-ray Diagnostic System
FDX Visionary-A

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024